JP2017533223A5 - - Google Patents

Download PDF

Info

Publication number
JP2017533223A5
JP2017533223A5 JP2017523507A JP2017523507A JP2017533223A5 JP 2017533223 A5 JP2017533223 A5 JP 2017533223A5 JP 2017523507 A JP2017523507 A JP 2017523507A JP 2017523507 A JP2017523507 A JP 2017523507A JP 2017533223 A5 JP2017533223 A5 JP 2017533223A5
Authority
JP
Japan
Prior art keywords
day
composition
administered
platin
taxane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017523507A
Other languages
English (en)
Japanese (ja)
Other versions
JP6698648B2 (ja
JP2017533223A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/057062 external-priority patent/WO2016069392A1/en
Publication of JP2017533223A publication Critical patent/JP2017533223A/ja
Publication of JP2017533223A5 publication Critical patent/JP2017533223A5/ja
Application granted granted Critical
Publication of JP6698648B2 publication Critical patent/JP6698648B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017523507A 2014-10-29 2015-10-23 ユビキチン活性化酵素阻害物質及び化学療法剤の投与 Expired - Fee Related JP6698648B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462072311P 2014-10-29 2014-10-29
US62/072,311 2014-10-29
PCT/US2015/057062 WO2016069392A1 (en) 2014-10-29 2015-10-23 Administration of ubiquitin-activating enzyme inhibitor and chemotherapeutic agents

Publications (3)

Publication Number Publication Date
JP2017533223A JP2017533223A (ja) 2017-11-09
JP2017533223A5 true JP2017533223A5 (enExample) 2018-11-29
JP6698648B2 JP6698648B2 (ja) 2020-05-27

Family

ID=55858197

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017523507A Expired - Fee Related JP6698648B2 (ja) 2014-10-29 2015-10-23 ユビキチン活性化酵素阻害物質及び化学療法剤の投与

Country Status (5)

Country Link
US (1) US20180133221A1 (enExample)
EP (1) EP3212650B1 (enExample)
JP (1) JP6698648B2 (enExample)
TW (1) TW201625256A (enExample)
WO (1) WO2016069392A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
TW202530228A (zh) 2023-10-12 2025-08-01 美商銳新醫藥公司 Ras抑制劑
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA024006B1 (ru) * 2006-02-02 2016-08-31 Миллениум Фармасьютикалз, Инк. Ингибиторы е1 активирующих ферментов
US8008307B2 (en) * 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
CA2864672C (en) * 2012-02-17 2018-01-09 Millennium Pharmaceuticals, Inc. Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme

Similar Documents

Publication Publication Date Title
JP2017533223A5 (enExample)
JP2017533221A5 (enExample)
Helm et al. Enhancing the efficacy of cisplatin in ovarian cancer treatment–could arsenic have a role
FI4403228T3 (fi) Her2:n dimerisaation estäjä pertutsumabin käyttötapoja ja sitä sisältävä tuote
JP2015533176A5 (enExample)
JP2009514881A5 (enExample)
ME02470B (me) Nanočesтice nabijene sa hemoterapeutskim anтitumorskim lekom
JP2014512356A5 (enExample)
JP2006504723A5 (enExample)
JP2012520323A5 (enExample)
JP2005511597A5 (enExample)
HK1222297A1 (zh) 一种包含ampk激活剂及血清素活性制剂之医药组合物及其用途
RU2013148732A (ru) Комбинации соединений, ингибирующих акт, и химиотерапевтических агентов и способы их применения
RU2013102398A (ru) Лечение рака крови
JP2010270124A5 (enExample)
JP2013523656A5 (enExample)
JP2016520528A5 (enExample)
NZ630392A (en) Methods of treating lung cancer
JP2017514800A5 (enExample)
JP2019536767A (ja) エピカテキン及び抗癌化合物の組合せを含む組成物
Misiukiewicz et al. Taxanes in cancer of the head and neck
JP2019506392A5 (enExample)
JP2017527582A5 (enExample)
RU2017141536A (ru) Замещенные производные индол-5-ола и их терапевтические применения
JP2015514756A5 (enExample)